The North America malaria treatment market is expected to grow from US$ 765.63 million in 2022 to US$ 996.80 million by 2028. It is estimated to register a CAGR of 4.5% from 2022 to 2028.

Rapid Diagnostic Tests for Malaria is Bolstering the North America Malaria Treatment Market

RDTs for malaria can improve the quality of management of the disease. RDTs are proven to be highly affordable and effective for public health programs implemented in low-resource settings. RDTs are widely used in remote areas with limited access to microscopy services. As a result, there has been a rapid rise in the demand for RDTs for malaria. Several RDTs have been developed to test the presence of malaria parasites in blood samples. Identifying and successfully treating malaria in low-transmission areas is critical to reduce transmission and eliminate the disease. Many companies are engaged in developing a wide range of RDTs with high sensitivities. A few of these developments have taken place in recent years. For instance, in November 2020, researchers from Rice University developed a simple microneedle patch like a bandage to detect malaria. With this development, the researchers have stepped on the path of reducing the disease burden in countries struggling with poor health infrastructure. The microneedles loaded on the patch collect interstitial fluid, which contains several biomarkers that help detect malaria. So, the growing number of rapid diagnostic tests for malaria is driving the North America malaria treatment market .

North America Malaria Treatment Market Overview

The North America malaria treatment market is segmented into the US, Canada, and Mexico. The US is dominating the malaria treatment market in the region. According to the Centers for disease control and prevention (CDC), approximately 2,000 cases are reported annually in the United States, mostly in returning travelers and immigrants. Pregnant women and children under five years of age are at the highest risk of contracting malaria and developing severe diseases. Anopheles mosquitoes capable of transmitting malaria ("vectors") endure in the US. Thus, there is a perpetual risk that malaria transmission can resume in the US. In April 2022, the Global Fund reported that malaria cases and deaths had risen primarily due to stalled funding and disruptions from the COVID-19 pandemic. However, efforts to mitigate these impacts are in progress, with the Global Fund reporting in September 2022 that programs had recovered from declines. US malaria efforts include activities primarily through the US President’s Malaria Initiative (PMI), overseen by the US Global Malaria Coordinator, and other US activities. For instance, according to Global health policy, US funding for malaria control and research activities was ~US$ 1 billion in FY 2022. The US government’s goal under the PMI Strategy 2021–2026 is to work and reduce malaria deaths further and decrease malaria morbidity toward the long-term goal of elimination. Thus, growing DVT cases and technological advancements in DVT preventive pumps are driving the market’s growth.

North America Malaria Treatment Market Revenue and Forecast to 2028 (US$ Million)

North America Malaria Treatment Market Segmentation

The North America malaria treatment market is segmented based on treatment, drug type, route of administration, distribution channel, end user, and country.

Based on treatment, the North America malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held the largest market share in 2022. The prescription medications segment is categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.

Based on drug type, the North America malaria treatment market is bifurcated into branded and generic. The generic segment held a larger market share in 2022.

Based on route of administration, the North America malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held a larger market share in 2022.

Based on distribution channel, the North America malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on end user, the North America malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held the largest market share in 2022.

Based on country, the North America malaria treatment market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US dominated the market in 2022.

AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, VLP Therapeutics LLC, and Zydus Healthcare Ltd are among the leading companies operating in the North America malaria treatment market.